Recurrent nasopharyngeal carcinoma: A clinical dilemma and challenge

Current Oncology

Volumn 20, Issue 5, 2013, Pages

  Xu, Tao ^a,b   Tang, J ^a   Gu, Mofa ^c   Liu, L ^c   Wei, W ^a   Yang, Huiling ^b  

^a THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biotherapy; Chemotherapy; Nasopharyngeal carcinoma; Radiotherapy; Recurrence; Surgery

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYUREA; IFOSFAMIDE; NEDAPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; DRUG SAFETY; EARLY DIAGNOSIS; ENDOSCOPIC SURGERY; FEBRILE NEUTROPENIA; GOLD STANDARD; HAND FOOT SYNDROME; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NEUTROPENIA; NONHUMAN; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RECURRENT CANCER; SALVAGE THERAPY; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

EID: 84886882751     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1456     Document Type: Article

References (103)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005;365:2041-54.
2. Su SF, Han F, Zhao C, et al. Treatment outcomes for different subgroups of nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy. Chin J Cancer 2011;30:565-73.
3. Lee AW, Foo W, Law SC, et al. Total biological effect on late reactive tissues following reirradiation for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;46:865-72.
4. Li JX, Lu TX, Huang Y, et al. Clinical features of 337 patients with recurrent nasopharyngeal carcinoma [Chinese]. Chin J Cancer 2010;29:82-6.
5. Yang TS, Ng KT, Wang HM, Wang CH, Liaw CC, Lai GM. Prognostic factors of locoregionally recurrent nasopharyngeal carcinoma-a retrospective review of 182 cases. Am J Clin Oncol 1996;19:337-43.
6. Chang JT, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2000;54:135-42.
7. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Ver. 1.2012. Fort Washington, PA: nccn: 2012. [Most recent version available online at: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (registration required); cited November 30, 2012]
8. Lee AW, Foo W, Law SC, et al. Recurrent nasopharyngeal carcinoma: the puzzles of long latency. Int J Radiat Oncol Biol Phys 1999;44:149-56.
9. Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1998;41:1099-111.
10. Chua DT, Sham JS, Kwong DL, Wei WI, Au GK, Choy D. Locally recurrent nasopharyngeal carcinoma: treatment results for patients with computed tomography assessment. Int J Radiat Oncol Biol Phys 1998;41:379-86.
11. Hu FJ, Ge MH, Li P, et al. Unfavorable clinical implications of circulating CD44+ lymphocytes in patients with nasopharyngeal carcinoma undergoing radiochemotherapy. Clin Chim Acta 2012;413:213-18.
12. Mould RF, Tai TH. Nasopharyngeal carcinoma: treatments and outcomes in the 20th century. Br J Radiol 2002;75:307-39.
13. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704.
14. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15.
15. Hui EP, Ma BB, Leung SF, et al. Randomized phase ii trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-9.
16. Chua DT, Sham JS, Kwong PW, Hung KN, Leung LH. Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications. Int J Radiat Oncol Biol Phys 2003;56:177-83.
17. Lee AW, Foo W, Law SC, et al. Reirradiation for recurrent nasopharyngeal carcinoma: factors affecting the therapeutic ratio and ways for improvement. Int J Radiat Oncol Biol Phys 1997;38:43-52.
18. Chua DT, Wei WI, Sham JS, Cheng AC, Au G. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma. Head Neck 2003;25:585-94.
19. Li JX, Lu TX, Huang Y, Han F. Clinical characteristics of recurrent nasopharyngeal carcinoma in high-incidence area. ScientificWorldJournal 2012;2012:719754.
20. Langendijk JA, Bourhis J. Reirradiation in squamous cell head and neck cancer: recent developments and future directions. Curr Opin Oncol 2007;19:202-9.
21. Luo RZ, Liang XM, Zong YS, et al. Clinicopathological characteristics of locally recurrent nasopharyngeal carcinoma (analysis of 240 cases) [Chinese]. J Pract Oncol 2004;19:124-6.
22. Pak MW, To KF, Leung SF, van Hasselt CA. In vivo diagnosis of persistent and recurrent nasopharyngeal carcinoma by contact endoscopy. Laryngoscope 2002;112:1459-66.
23. Wang WH, Lin YC, Chen WC, Chen MF, Chen CC, Lee KF. Detection of mucosal recurrent nasopharyngeal carcinomas after radiotherapy with narrow-band imaging endoscopy. Int J Radiat Oncol Biol Phys 2012;83:1213-19.
24. Ng SH, Chang JT, Ko SF, Wan YL, Tang LM, Chen WC. mri in recurrent nasopharyngeal carcinoma. Neuroradiology 1999;41:855-62.
25. Liu T, Xu W, Yan WL, Ye M, Bai YR, Huang G. fdg-pet, ct, mri for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007;85:327-35.
26. Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G, Lise M. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of mr imaging and fdg pet/ct. Radiology 2008;249:203-11.
27. Ng SH, Chan SC, Yen TC, et al. Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-body mri at 3 T compared with fdg-pet-ct. Eur Radiol 2010;20:2229-40.
28. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus dna in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
29. Wang WY, Twu CW, Chen HH, et al. Plasma ebv dna clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16:1016-24.
30. Wei WI, Yuen AP, Ng RW, Ho WK, Kwong DL, Sham JS. Quantitative analysis of plasma cell-free Epstein-Barr virus dna in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study. Head Neck 2004;26:878-83.
31. Hao SP, Tsang NM, Chang KP. Monitoring tumor recurrence with nasopharyngeal swab and LMP-1 and EBNA-1 gene detection in treated patients of npc. Laryngoscope 2004;114:2027-30.
32. Yu KH, Leung SF, Tung SY, et al. on behalf of the Hong Kong Nasopharyngeal Carcinoma Study Group. Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 2005;27:397-405.
33. Oksüz DC, Meral G, Uzel O, Caǧatay P, Turkan S. Reirradiation for locally recurrent nasopharyngeal carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2004;60:388-94.
34. Hua YJ, Han F, Lu LX, et al. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. Eur J Cancer 2012;48:3422-8.
35. Han F, Zhao C, Huang SM, et al. Long-term outcomes and prognostic factors of re-irradiation for locally recurrent nasopharyngeal carcinoma using intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 2011;24:569-76.
36. Vlantis AC, Chan HS, Tong MC, Yu BK, Kam MK, van Hasselt CA. Surgical salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma: a multivariate analysis of prognostic factors. Head Neck 2011;33:1126-31.
37. Chua DT, Hung KN, Lee V, Ng SC, Tsang J. Validation of a prognostic scoring system for locally recurrent nasopharyngeal carcinoma treated by stereotactic radiosurgery. BMC Cancer 2009;9:131.
38. An X, Wang FH, Ding PR, et al. Plasma Epstein-Barr virus dna level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 2011;117:3750-7.
39. Lu H, Peng L, Yuan X, et al. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia. Cancer Treat Rev 2009;35:345-53.
40. Fang FM, Tsai WL, Chen HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques. Cancer 2007;109:313-21.
41. Hsiung CY, Yorke ED, Chui CS, et al. Intensity modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2002;53:638-47.
42. Lu TX, Mai WY, Teh BS, et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004;58:682-7.
43. Chua DT, Sham JS, Leung LH, Au GK. Re-irradiation of nasopharyngeal carcinoma with intensity-modulated radiotherapy. Radiother Oncol 2005;77:290-4.
44. Qiu S, Lin S, Tham IW, Pan J, Lu J, Lu JJ. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2012;83:676-83.
45. Zheng XK, Ma J, Chen LH, Xia YF, Shi YS. Dosimetric and clinical results of three-dimensional conformal radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2005;75:197-203.
46. Li JC, Hu CS, Jiang GL, et al. Dose escalation of threedimensional conformal radiotherapy for locally recurrent nasopharyngeal carcinoma: a prospective randomised study. Clin Oncol (R Coll Radiol) 2006;18:293-9.
47. Chua DT, Wu SX, Lee V, Tsang J. Comparison of single versus fractionated dose of stereotactic radiotherapy for salvaging local failures of nasopharyngeal carcinoma: a matched-cohort analysis. Head Neck Oncol 2009;1:13.
48. Seo Y, Yoo H, Yoo S, et al. Robotic system-based fractionated stereotactic radiotherapy in locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2009;93:570-4.
49. Roeder F, Zwicker F, Saleh-Ebrahimi L, et al. Intensity modulated or fractionated stereotactic reirradiation in patients with recurrent nasopharyngeal cancer. Radiat Oncol 2011;6:22.
50. Kung SW, Wu VW, Kam MK, et al. Dosimetric comparison of intensity-modulated stereotactic radiotherapy with other stereotactic techniques for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2011;79:71-9.
51. Taheri-Kadkhoda Z, Björk-Eriksson T, Nill S, et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiat Oncol 2008;3:4.
52. Feehan PE, Castro JR, Phillips TL, et al. Recurrent locally advanced nasopharyngeal carcinoma treated with heavy charged particle irradiation. Int J Radiat Oncol Biol Phys 1992;23:881-4.
53. Spencer SA, Harris J, Wheeler RH, et al. Final report of rtog 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30:281-8.
54. Teo PM, Kwan WH, Chan AT, Lee WY, King WW, Mok CO. How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 1998;40:897-913.
55. Leung TW, Tung SY, Sze WK, et al. Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;48:1331-8.
56. Wu SX, Chua DT, Deng ML, et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:761-9.
57. Leung TW, Wong VY, Tung SY. Stereotactic radiotherapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2009;75:734-41.
58. King WW, Ku PK, Mok CO, Teo PM. Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: a twelve-year experience. Head Neck 2000;22:215-22.
59. Fee WE Jr, Moir MS, Choi EC, Goffinet D. Nasopharyngectomy for recurrent nasopharyngeal cancer: a 2-to 17-year follow-up. Arch Otolaryngol Head Neck Surg 2002;128:280-4.
60. Hao SP, Tsang NM, Chang KP, Hsu YS, Chen CK, Fang KH. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors. Acta Otolaryngol 2008;128:473-81.
61. Wei WI, Chan JY, Ng RW, Ho WK. Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach-critical appraisal after 2 decades. Head Neck 2011;33:969-75.
62. Yoshizaki T, Wakisaka N, Murono S, Shimizu Y, Furukawa M. Endoscopic nasopharyngectomy for patients with recurrent nasopharyngeal carcinoma at the primary site. Laryngoscope 2005;115:1517-19.
63. Chen MK, Lai JC, Chang CC, Liu MT. Minimally invasive endoscopic nasopharyngectomy in the treatment of recurrent T1-2a nasopharyngeal carcinoma. Laryngoscope 2007;117:894-6.
64. Chen MY, Wen WP, Guo X, et al. Endoscopic nasopharyngectomy for locally recurrent nasopharyngeal carcinoma. Laryngoscope 2009;119:516-22.
65. Wei WI, Ho WK. Transoral robotic resection of recurrent nasopharyngeal carcinoma. Laryngoscope 2010;120:2011-14.
66. Yin Tsang RK, Ho WK, Wei WI. Combined transnasal endoscopic and transoral robotic resection of recurrent nasopharyngeal carcinoma. Head Neck 2012;34:1190-3.
67. Chen MY, Wang SL, Zhu YL, et al. Use of a posterior pedicle nasal septum and floor mucoperiosteum flap to resurface the nasopharynx after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma. Head Neck 2012;34:1383-8.
68. Chan JY, Chow VL, Tsang R, Wei WI. Nasopharyngectomy for locally advanced recurrent nasopharyngeal carcinoma: exploring the limits. Head Neck 2012;34:923-8.
69. Altundag K, Aksoy S, Gullu I, et al. Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy. Med Oncol 2004;21:211-15.
70. Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 2002;95:2516-23.
71. Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase ii study. Ann Oncol 2002;13:1252-8.
72. Chua DT, Kwong DL, Sham JS, Au GK, Choy D. A phase ii study of ifosfamide, 5-f luorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. Eur J Cancer 2000;36:736-41.
73. McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A phase ii trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 2002;38:686-90.
74. Chua DT, Sham JS, Au GK. A phase ii study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol 2003;39:361-6.
75. Wong ZW, Tan EH, Yap SP, et al. Chemotherapy with or without radiotherapy in patients with locoregionally recurrent nasopharyngeal carcinoma. Head Neck 2002;24:549-54.
76. Poon D, Yap SP, Wong ZW, et al. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004;59:1312-18.
77. Chua DT, Sham JS, Au GK. Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma. Am J Clin Oncol 2005;28:464-71.
78. Nakamura T, Kodaira T, Tachibana H, et al. Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma: treatment outcome and prognostic factors. Jpn J Clin Oncol 2008;38:803-9.
79. Chua D, Wei WI, Sham JS, Au GK. Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 2008;38:244-9.
80. Wang J, Li J, Hong X, et al. Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma. Oral Oncol 2008;44:464-70.
81. Ji JH, Yun T, Kim SB, et al. on behalf of the Korean Cancer Study Group (kcsg). A prospective multicentre phase ii study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (kcsg HN07-01). Eur J Cancer 2012;48:3198-204.
82. Yau TK, Shum T, Lee AW, Yeung MW, Ng WT, Chan L. A phase ii study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 2012;48:441-4.
83. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase iii randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-17.
84. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:11-20.
85. Ma BB, Poon TC, To KF, et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and her2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 2003;25:864-72.
86. Xueguan L, Xiaoshen W, Yongsheng Z, Chaosu H, Chunying S, Yan F. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor expression are associated with a poor prognosis in patients with nasopharyngeal carcinoma receiving radiotherapy with carbogen and nicotinamide. Clin Oncol (R Coll Radiol) 2008;20:606-12.
87. Krishna SM, James S, Balaram P. Expression of vegf as prognosticator in primary nasopharyngeal cancer and its relation to ebv status. Virus Res 2006;115:85-90.
88. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the pi3-k/Akt pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288-96.
89. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
90. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
91. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
92. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase ii study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-76.
93. Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J, Au GK. Phase ii s tudy o f g efitinib f or t he t reatment o f r ecurrent and metastatic nasopharyngeal carcinoma. Head Neck 2008;30:863-7.
94. Ma B, Hui EP, King A, et al. A phase ii study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus dna as a biomarker of efficacy. Cancer Chemother Pharmacol 2008;62:59-64.
95. You B, Le Tourneau C, Chen EX, et al. A phase ii trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol 2012;35:255-60.
96. Lim WT, Ng QS, Ivy P, et al. A phase ii study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res 2011;17:5481-9.
97. Elser C, Siu LL, Winquist E, et al. Phase ii trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-73.
98. Chua D, Huang J, Zheng B, et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 2001;94:73-80.
99. Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005;105:1898-904.
100. Hua YJ, Chen MY, Qian CN, et al. Postradiation nasopharyngeal necrosis in the patients with nasopharyngeal carcinoma. Head Neck 2009;31:807-12.
101. Cengiz M, Ozyar E, Esassolak M, et al. Assessment of quality of life of nasopharyngeal carcinoma patients with eortc qlq-C30 and H&N-35 modules. Int J Radiat Oncol Biol Phys 2005;63:1347-53.
102. Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys 2008;72:356-64.
103. Chan YW, Chow VL, Wei WI. Quality of life of patients after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma. Cancer 2012;118:3710-18.